Celldex Therapeutics
CLDX
Celldex Therapeutics (CLDX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $64.00 | Oct 2, 2026 |
| Morgan Stanley | Maintained | Overweight | $57.00 from $50.00 | Sep 23, 2026 |
| Leerink Partners | Maintained | Outperform | $88.00 from $70.00 | Sep 23, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $72.00 from $61.00 | Sep 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $64.00 from $42.00 | Sep 22, 2026 |
| Morgan Stanley | Maintained | Overweight | $50.00 from $46.00 | Sep 10, 2026 |
| Barclays | Maintained | Overweight | $53.00 from $48.00 | Aug 7, 2026 |
| Morgan Stanley | Maintained | Overweight | $46.00 from $40.00 | Aug 7, 2026 |
| Wells Fargo | Maintained | Overweight | $72.00 from $48.00 | Jul 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $60.00 from $62.00 | Jul 22, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $61.00 from $67.00 | Jul 22, 2026 |
| Morgan Stanley | Maintained | Overweight | $40.00 from $44.00 | Jul 22, 2026 |
| Wells Fargo | Maintained | Overweight | $48.00 from $54.00 | Jul 22, 2026 |
| Guggenheim | Maintained | Buy | $100.00 from $90.00 | Jul 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $42.00 | Jun 15, 2026 |
| UBS | Maintained | Buy | $45.00 from $38.00 | Jun 10, 2026 |
| Wells Fargo | Maintained | Overweight | $54.00 from $38.00 | May 13, 2026 |
| Barclays | Maintained | Overweight | $48.00 from $45.00 | May 8, 2026 |
| Barclays | Upgraded | Underweight → Overweight | $45.00 from $24.00 | Apr 20, 2026 |
| Goldman Sachs | Maintained | Neutral | $34.00 from $30.00 | Mar 2, 2026 |
Frequently asked questions
What is the latest analyst rating on CLDX?
On Oct 2, 2026, HC Wainwright & Co. maintained Celldex Therapeutics at Buy with a price target of $64.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.